FDA approves Sun Pharma's JAK inhibitor Leqselvi for hair loss in adults
Sun Pharma’s $576 million acquisition of Concert Pharmaceuticals is paying off with an FDA approval of the alopecia drug that came with the 2023 deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
